March 3, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Cognitive Training Paired With tDCS Aids Patients Electrically stimulating the brain while doing at-home cognitive training games can help to prevent a decline in cognition for people with multiple sclerosis (MS), particularly those with more advanced disability, a study indicates. “This could lead to a…
March 3, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Tolebrutinib More Potent Than Other BTK Blockers Tolebrutinib, an investigative inhibitor of Bruton’s tyrosine kinase (BTK) being developed by Sanofi to treat all forms of multiple sclerosis (MS), shows the potential to be more potent than other BTK inhibitors also in advanced clinical trials, scientists reported.
March 2, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Algorithm Predicts Relapse Risk Using EHR Data Using a two-step machine learning strategy, researchers have developed an algorithm to predict the risk of multiple sclerosis (MS) relapse based on data gleaned from electronic health records. “The two-step machine learning model predicts a patient’s future one-year…
March 2, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Hormone Therapies May Benefit Menopausal MS Patients Hormonal changes over time — and especially those around menopause — are often associated with disability worsening in multiple sclerosis (MS) patients, which suggests that sex-specific hormone therapies may be useful in MS treatment. Burcu Zeydan, MD, assistant…
March 2, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Ublituximab Eases Brain Lesions Better Than Aubagio The experimental medication ublituximab significantly reduces the number of new brain lesions with severe nerve cell degeneration in people with relapsing multiple sclerosis (MS) as compared with Aubagio (teriflunomide), according to new data from the Phase 3…
March 1, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Cortical Lesions Seen to Predict Disability Worsening A higher burden of lesions in the brain’s cortex is associated with a greater likelihood of disability worsening in multiple sclerosis (MS) and transition to secondary progressive MS (SPMS), researchers report. These results suggest that “monitoring cortical…
March 1, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Spinal Cord Atrophy Predicts ‘Silent Progression’ in Early MS A faster rate of atrophy in the spinal cord of people in earlier stages of multiple sclerosis (MS) is likely to indicate “silent progression” — worsening disability in the absence of relapses — and a swifter conversion to…
February 28, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Mavenclad Best at Reducing Relapses: Real-world Data People with multiple sclerosis (MS) who are treated with Mavenclad (cladribine) are less likely to experience a disease relapse than those who are treated with Gilenya (fingolimod), Tecfidera (dimethyl fumarate), or Aubagio (teriflunomide), according to an analysis…
February 28, 2022 News by Marisa Wexler, MS #ACTRIMS2022 – Iron Rim Lesions Linked to More Severe Disease Iron rim lesions, or specific regions of chronic inflammation seen on MRI scans of the brain, are associated with greater disability and poorer outcomes in multiple sclerosis (MS), a study indicates. These findings “could support the use of…